← Human Trials & Peer-Reviewed Studies
Application Effect of Somatostatin Combined with Transnasal Ileus Catheterization in Patients with Acute Intestinal Obstruction and Advanced Gastric Cancer.
Plain-language guide to PMID 35726291 (2022): randomized controlled trial of Somatostatin in 94 patients.
Key Facts
- PMID
- 35726291
- Journal
- Computational intelligence and neuroscience
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Li Z et al. (3 authors)
- DOI
- 10.1155/2022/9747880
What This Study Did, in Plain Language
What Was Tested
Researchers studied Somatostatin in this randomized controlled trial publication.
Objective: To explore the application of somatostatin combined with nasal plug catheterization in patients with advanced gastric cancer and acute intestinal obstruction.
Why It Was Studied
This study included 94 cases of patients with acute intestinal obstruction and advanced gastric cancer, and according to the length of hospital stay, the patients were randomly divided into two groups: the control group and the study group, with 47 cases in each group.
Based on the observations made by the team in the control group given somatostatin combined treatment, the researchers observed two groups of patients with gastrointestinal function, serum index, quality of life, therapeutic effect, and adverse reactions.
Who Took Part
The study group was 94 patients.
How the Study Was Run
The design is described as randomized.
The patients were allocated by chance, so the Somatostatin group and the comparison group should start out alike.
What Was Measured
This study included 94 cases of patients with acute intestinal obstruction and advanced gastric cancer, and according to the length of hospital stay, the patients were randomly divided into two groups: the control group and the study group, with 47 cases in each group.
Based on the observations made by the team in the control group given somatostatin combined treatment, the researchers observed two groups of patients with gastrointestinal function, serum index, quality of life, therapeutic effect, and adverse reactions.
The subject headings attached to it are Catheterization, Ileus, Intestinal Obstruction, Quality of Life, Somatostatin and Stomach Neoplasms.
What This Means in Plain Language
The paper is a randomized study of Somatostatin in 94 patients.
The publication is from 2022 (Computational intelligence and neuroscience), a journal based in United States.
More context: the Somatostatin compound page, all human trials.
Our Notes on the Compound
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.